Journal
JOURNAL OF CLINICAL LIPIDOLOGY
Volume 4, Issue 5, Pages 411-419Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2010.08.004
Keywords
apoAI; CETP; Cholesterol efflux; HDL; LXR; Reverse cholesterol transport
Categories
Funding
- Merck
- Glaxo
- Abbott
- Pfizer
- ISIS
- Astra-Zeneca
Ask authors/readers for more resources
The field of cardiovascular prevention has long anticipated the evolution of high-density lipoprotein (HDL) therapy from unproven metabolic tweaking to pillar of risk reduction on par with low-density lipoprotein control. However, the convincing epidemiologic data linking HDL cholesterol (HDL-C) and cardiovascular disease risk in an inverse correlation has not yet translated into clinical trial evidence supporting linearity between HDL-C increases and risk reduction, or identifying obvious goals of therapy. Although HDL-C-increasing lifestyle maneuvers and established HDL drugs such as niacin and fibrates are likely to protect the vasculature, the negative results obtained in trials of a cholesteryl ester transfer protein inhibitor remind us that HDL-C increases are not always beneficial. It is becoming clear that a functional HDL is a more desirable target than simply increasing HDL-C levels. The larger objective of improving HDL functionality (with or without HDL-C level changes) is bound to become the guiding principle for pharmaceutical research in this area. Several new compounds currently being tested bridge the classical aim of increasing HDL-C levels with the novel target of improving HDL function. (C) 2010 National Lipid Association. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available